Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 3/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA5A | P35218 | 3/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13183572 | 0.83 | NOTUM (0.59) | NOTUMLRRK2FLT3CA1CA2 | |
| SCHEMBL13183643 | 0.81 | ESRRA (0.52) | ESRRANOTUMFLT3 | |
| SCHEMBL12179482 | 0.80 | MIF (0.53) | ESRRANOTUM | |
| SCHEMBL14611001 | 0.80 | NOTUM (0.56) | NOTUMFLT3PTGS2P2RX7 | |
| SCHEMBL2683483 | 0.80 | FLT3 (0.50) | NOTUMFLT3CA1CA2CA5A | |
| SCHEMBL18865699 | 0.79 | NOTUM (0.46) | NOTUMFLT3CA1CA2CA12 | |
| SCHEMBL2629357 | 0.79 | P2RX7 (0.55) | ESRRANOTUMFLT3CA1CA2 | |
| SCHEMBL3340257 | 0.78 | KDM4E (0.49) | ESRRANOTUMLRRK2 | |
| SCHEMBL29640824 | 0.78 | MAPT (0.44) | NOTUMLRRK2FLT3CA1CA2 | |
| SCHEMBL21275488 | 0.78 | MAPT (0.44) | NOTUMLRRK2FLT3CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109476670-B | Bicyclic heteroaryl derivatives | 豪夫迈·罗氏有限公司 | 2022-06-28 | — | — | CN | disclosed |
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | E-THERAPEUTICS PLC (GB) | 2021-08-05 | — | — | US | disclosed |
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | E-THERAPEUTICS PLC (GB) | 2021-08-05 | — | — | US | disclosed |
| EP-3523304-B1 | BICYCLIC HETEROARYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| US-10647721-B2 | Bicyclic heteroaryl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190233427-A1 | BICYCLIC HETEROARYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-08-01 | — | — | US | disclosed |
| US-20160362392-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362392-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362392-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-9452999-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2016-09-27 | — | — | US | disclosed |
| WO-2012107850-A1 | GLUCAGON RECEPTOR MODULATOR | PFIZER INC. (US) | 2012-08-16 | — | — | WO | disclosed |
| US-20120202834-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202834-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202834-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20100298312-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298312-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298312-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2200436-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | The Scripps Research Institute (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009032861-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032861-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | TPH1, KYNU, TPH2 | ESRRA 3634/4885NOTUM 1961/4885LRRK2 762/4885 |
| US-20190233427-A1 | BICYCLIC HETEROARYL DERIVATIVES | HUWE1, CDR2, DBH | ESRRA 2620/4885NOTUM 3424/4885LRRK2 1379/4885 |
| US-20100298312-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K5, MAP3K7 | ESRRA 4511/4885NOTUM 3648/4885LRRK2 333/4885 |
| US-20160362392-A1 | GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | ESRRA 263/4885NOTUM 4691/4885LRRK2 313/4885 |
| US-10647721-B2 | Bicyclic heteroaryl derivatives | HUWE1, CDR2, DBH | ESRRA 2620/4885NOTUM 3424/4885LRRK2 1379/4885 |
| US-20120202834-A1 | GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | ESRRA 263/4885NOTUM 4691/4885LRRK2 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.